Circulatory and platelet actions of 6,9-Thiaprostacyclin (PGI2-S) in the cat

Allan M. Lefer, George J. Trachte, J. Bryan Smith, William E. Barnette, K. C. Nicolaou

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


A new analog of prostacyclin, 6,9-Thiaprostacyclin was infused intravenously in pentobarbital anesthetized cats in order to determine its hemodynamic and anti-platelet aggregating properties. At an infusion rate of 0.01 μmoles/kg/min, PGI2-S moderately decreased arterial blood pressure without altering heart rate of superior mesenteric artery flow or platelet aggregation responses to ADP. However, at 0.05 μmoles/kg/min, PGI2-S significantly reduced arterial blood pressure and significantly increased heart rate, and superior mesenteric artery flow. Moreover, at 0.05 μmoles/kg/min, PGI2-S inhibited ADP platelet aggregation by 80%. PGI2-S may be a useful agent in circulatory shock.

Original languageEnglish (US)
Pages (from-to)259-263
Number of pages5
JournalLife Sciences
Issue number3
StatePublished - Jul 16 1979

Bibliographical note

Funding Information:
Adult male cats (2.5 to 3.5 kg) were anesthetized with pentobarbital sodium (30 mg/kg) given intravenously. Supplemental anesthetic was given as Supported in part by NHLBI Institute Contract No . HO-E 2931 from the NIH and by the Ischemia-Shock Research Institute of Thomas Jefferson University .


Dive into the research topics of 'Circulatory and platelet actions of 6,9-Thiaprostacyclin (PGI2-S) in the cat'. Together they form a unique fingerprint.

Cite this